Cold subcutaneous abscesses as the first manifestation of disseminated coccidioidomycosis in an immunocompromised host. (25th November 2015)

• Record Type: Journal Article
• Authors: Garza‐Chapa, Juana Irma; Martínez‐Cabriales, Sylvia Aide; Ocampo‐Garza, Jorge; Gómez‐Flores, Minerva; Ocampo‐Candiani, Jorge; Welsh, Oliverio
• Is Part Of: Australasian journal of dermatology. Volume 57:Number 2(2016)
• Page Start: e49
• Page End: e52
• Publication Date: 2015-11-25
• Subjects: coccidioidomycosis -- cold subcutaneous abscesses -- disseminated coccidioidomycosis -- immunocompromised host -- systemic lupus erythematosus; Dermatology -- Periodicals; Dermatology -- Australasia -- Periodicals; 616.5005
• DOI: 10.1111/ajd.12424
• Languages: English
• ISSNs: 0004-8380

Abstract

Abstract: Coccidioidomycosis is an endemic fungal infection in the southwestern USA and northern Mexico. It is caused by C occidioides immitis and C . posadasii. This infection occurs due to the inhalation of airborne arthroconidia, causing a mild pulmonary infection, but most cases are asymptomatic. Disseminated coccidioidomycosis (DC) is a rare entity occurring in less than 1% of all cases, usually in immunocompromised patients, and it carries high risks of morbidity and mortality. The skin is one of the most frequently affected organs and in some cases cutaneous lesions may be the first or only sign of infection. A wide spectrum of clinical lesions may develop, including cold abscess. In immunocompromised hosts, DC represents a diagnostic and therapeutic challenge. Treatment is based on antifungal drugs, such as amphotericin B and azoles, administered for long periods of time and under close follow up to monitor the treatment response and to detect relapse. In the following case report, we present a 35‐year‐old male patient with systemic lupus erythematosus under immunosuppressive therapy who presented with cold subcutaneous abscesses as the first sign of DC.